Enzymatica receives record order from STADA Arzneimittel AG
(Thomson Reuters ONE) -
Press release
Lund, June 14, 2017
Enzymatica has received its largest order to date for a total of about SEK 12
million. The global pharmaceutical company STADA Arzneimittel AG ("STADA"),
headquartered in Germany, has ordered Enzymatica's cold product ColdZyme® Mouth
spray for the German, Belgian and Austrian markets for the common cold season
after the summer.
The order is a result of the cooperation agreement that Enzymatica and STADA
reached in February 2017. The agreement grants STADA exclusive rights to sell,
market and distribute ColdZyme in Germany, the largest market for OTC products
in Europe, as well as in Belgium and Austria.
"We are now beginning to see the results of our efforts to sign agreements with
international distributors for the major OTC markets. The order is the largest
in Enzymatica's history and is worth much more than the entire sales of SEK 9.6
million for the first quarter this year. The order confirms the commercial
potential of ColdZyme and our technology platform," says Fredrik Lindberg, CEO
of Enzymatica.
Enzymatica expects to deliver the order at the end of the summer and the revenue
will have an impact on the company's third quarter sales.
STADA is a publicly-listed German company with a traditionally strong presence
in Europe, especially in Germany. STADA is an international company and its five
largest markets are Germany, Russia, the UK, Italy and Spain. In 2016 the STADA
Group generated sales of EUR 2,139 million and had 10,839 employees all over the
world.
The information in this press release is information that Enzymatica is obliged
to make public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person set out
below, on June 14, 2017 at 08.00.
For more information please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg(at)enzymatica.com
About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells medical
devices for infection-related diseases. In just a short period of time, the
company developed ColdZyme®, a unique mouth spray for colds, launched the
product in eight countries and became established among the top-selling cold
products (denominated in SEK) at Swedish pharmacies. The strategy is to continue
to grow by strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners. The company
is headquartered in Lund and is listed on Nasdaq First North. For more
information please visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser Bank.
Press Release (PDF):
http://hugin.info/160850/R/2112995/803785.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 547815
Anzahl Zeichen: 3476
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Enzymatica receives record order from STADA Arzneimittel AG"
steht unter der journalistisch-redaktionellen Verantwortung von
Enzymatica AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
